经腔静脉栓塞治疗EVAR后II型内漏:肾下、近肾及IV型胸腹主动脉瘤的结局
本研究回顾性分析了24例患者共25次经腔静脉栓塞(TCE)手术,用于治疗肾下EVAR及开窗/分支EVAR(F/BEVAR)后因II型内漏导致的瘤囊增大(≥5mm)。技术成功率96.0%,院内并发症及30天死亡率为0%,中位随访23.1个月,12个月免于II型内漏相关再干预率为84.6%。结论认为TCE是伴有瘤囊增大的II型内漏可接受的治疗选择。
要点
- TCE技术成功率达96.0%,院内并发症和30天死亡率为0%。
- 12个月免于II型内漏相关再干预率为84.6%。
- 非选择性与选择性TCE后再干预率分别为16.7%和20%。
核心结论
- TCE是伴有瘤囊增大的II型内漏可接受的治疗选择。
- TCE可用于肾下腹主动脉瘤EVAR后及近肾腹主动脉瘤和IV型胸腹主动脉瘤F/BEVAR后的II型内漏。
研究设计与样本
- 回顾性单中心队列研究,纳入2015年8月至2019年8月间所有连续TCE手术。
- 共纳入24例患者的25次TCE手术,男性占95.8%。
- TCE指征为肾下EVAR或近肾/IV型胸腹主动脉瘤F/BEVAR后因II型内漏导致瘤囊增大≥5mm。
主要发现
- 技术成功率为96.0%(24/25)。
- 选择性和非选择性TCE分别在48%的患者中实施。
- 院内并发症和30天死亡率均为0%。
- 中位随访23.1个月(IQR 10.9-40.1个月),12个月免于II型内漏相关再干预率为84.6%。
- 非选择性TCE后再干预率为16.7%,选择性TCE后为20%;EVAR后为12.5%,F/BEVAR后为33.3%。
临床怎么用
- 对于EVAR或F/BEVAR后因II型内漏导致瘤囊增大≥5mm的患者,可考虑行TCE。
- TCE术后需随访监测内漏相关再干预。
局限性
- 回顾性单中心设计,样本量较小(24例患者,25次手术)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aims to determine the outcomes of transcaval embolization (TCE) for type II endoleak after infrarenal endovascular aortic repair (EVAR) and fenestrated/branched EVAR (F/BEVAR). METHODS: A retrospective single-center cohort study of all consecutive TCE procedures between August 2015 and August 2019 was performed to investigate technical success, in-hospital morbidity, and 30-day mortality as well as clinical success during follow-up. The indication for TCE was an aneurysm sac growth of 5 mm or more owing to a type II endoleak after EVAR for infrarenal or F/BEVAR for juxtarenal and type IV thoracoabdominal aortic aneurysm. RESULTS: A total 25 TCE procedures in 24 patients (95.8% male) were included. Technical success was 96.0% (24/25); selective and nonselective TCE were performed in 48% of patients. The in-hospital morbidity and 30-day mortality were 0%. The median follow-up was 23.1 months (interquartile range, 10.9-40.1 months). Freedom from type II endoleak-related reintervention was 84.6% at 12 months. Comparing clinical success after TCE, reintervention was necessary in 16.7% of patients after nonselective and 20% of patients after selective TCE. Regarding TCE after EVAR vs F/BEVAR, reintervention was performed in 12.5% of EVAR and 33.3% of F/BEVAR patients during follow-up. CONCLUSIONS: TCE is an acceptable treatment alternative for type II endoleak with aneurysm sac enlargement and can be used after EVAR for infrarenal abdominal aortic aneurysms and F/BEVAR for juxtarenal abdominal aortic aneurysms and type IV thoracoabdominal aortic aneurysms.
引用
- Heidemann F, Rohlffs F, Tsilimparis N, et al. Transcaval embolization for type II endoleak after endovascular aortic repair of infrarenal, juxtarenal, and type IV thoracoabdominal aortic aneurysm. J Vasc Surg. 2021. PMID: 33348001. doi:10.1016/j.jvs.2020.12.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。